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Rapid evidence review of harm reduction 
interventions and messaging for people 
who inject drugs during pandemic events: 
implications for the ongoing COVID-19 
response
Rebecca Wilkinson1* , Lindsey Hines2, Adam Holland3, Sema Mandal4 and Emily Phipps5
Abstract 
Background: People who inject drugs are at increased health risk in a pandemic due to their greater susceptibility 
to severe disease and as a consequence of the restrictions put in place to halt the spread of infection. Harm reduction 
(HR) services, which aim to reduce the negative effects of drug use on health, are likely to be diminished in a pan-
demic. However, innovative HR interventions and messaging may also develop in response to such a crisis. It is vital to 
understand the most effective ways to deliver HR in pandemic situations so that guidance can be provided for current 
and future disruptions to service provision.
Methods: A rapid evidence review was conducted with the aim of exploring what HR interventions and messaging 
are most effective during a pandemic-type situation. Ten health databases were systematically searched using terms 
relevant to the research aim. A search was also made of grey literature, including a targeted search of HR messaging 
from key national and service provider websites.
Results: In the initial search, 121 pieces of evidence were identified which, after screening and de-duplication, 
resulted in 60 for inclusion. The included evidence consists mainly of non-peer reviewed, pre-publication or expert 
opinion pieces. The rapid findings suggest that HR services should be deemed essential during a pandemic, with staff 
supported to work safely and social distancing adaptations implemented. Services should be encouraged to operate 
more flexibly; for instance, in deciding the amounts of take-home supplies of injecting equipment and medications. 
The evidence on HR communication was very limited but key messages on infection control, uncertain drug supply 
and accessing services were identified.
Conclusions: This rapid evidence review identifies implications for national policy makers, commissioners and HR 
service providers. A person-centred rather than disease-centred approach to HR delivered by collaborating partners, 
as well as prioritizing tailored HR messaging, is recommended. Further research evaluating the delivery of HR services 
and messaging, particularly focusing on health inequalities, is urgently needed.
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Background
A novel coronavirus, severe acute respiratory syn-
drome coronavirus 2, which causes coronavirus dis-
ease 2019 (COVID-19), was isolated in December 2019 
and declared as a global pandemic by the World Health 
Organization (WHO) in March 2020 [1]. The impact 
of COVID-19 and the measures required to combat it 
are disproportionately felt by society’s most vulnerable 
populations. People who inject drugs (PWID) are likely 
to have a number of characteristics that make them 
more vulnerable, such as living on low incomes and in 
poor quality, crowded situations where social distanc-
ing is difficult. In addition, PWID are more likely to 
have physical and mental health comorbidities that may 
render them at increased risk of infection, more severe 
disease and worse outcomes [2].
Harm reduction (HR) can be defined as a public 
health approach which prioritizes reducing the negative 
effects of drug use rather than eliminating it or attain-
ing abstinence [3]. HR interventions include needle and 
syringe programmes (NSP), opioid substitution therapy 
(OST) and provision of naloxone as an emergency anti-
dote to opiate overdose.
During the COVID-19 pandemic, many HR services 
were reduced or suspended completely in order to 
redeploy staff or facilitate the social distancing required 
to curb the spread of infection. However, in some areas 
innovative HR interventions and messaging were devel-
oped in response to the crisis. The impact of the pan-
demic, and these associated service changes, on PWID 
is not yet known but it is likely that there will have been 
a worsening of outcomes [2, 4, 5]. Therefore, it is vital 
that lessons are learnt quickly about the most effective 
ways to deliver HR in  situations such as the COVID-
19 pandemic so that guidance can be provided for the 
ongoing COVID-19 response and similar outbreaks.
This report presents preliminary findings from a rapid 
review of the available evidence (up until 14/08/2020). 
The aim of the review was to identify which HR inter-
ventions and messages for PWID are most effective 
during situations such as a global pandemic.
Methods
This rapid evidence review was undertaken at speed to 
address the urgent need for evidence and guidance on 
delivery of HR services and messaging for PWID dur-
ing a pandemic.
The review protocol was registered with PROSPERO 
[6].
Databases searched between 10 and 14 August 2020 
were PROSPERO, Cochrane, TRIP, Medline, PsycInfo, 
Web of Science, EMBASE, PubMed, OpenGrey, PLOS 
and Google Scholar, and Table 1 summarizes the search 
terms used (full details of the searches are included in 
Appendix 1—see Additional file 1).
Broad inclusion criteria were used as the scoping 
searches indicated a lack of peer-reviewed studies. 
Thus, grey literature, pre-publication and non-peer 
reviewed papers were also included as well as evidence 
suggested by experts in the field. The searches were, 
however, restricted to English language only.
The scoping searches revealed a lack of evidence on 
messaging specifically directed at PWID, so a targeted 
search (via Google) was conducted for COVID-19-re-
lated HR messaging from key national public health 
bodies and drug service providers.
The evidence was screened initially (RW) on whether 
the title alone appeared to have relevance to the 
research aim. The second screen (RW and AH) was 
based on abstract or summary and used the inclu-
sion criteria detailed in Table  2. The search was not 
restricted to studies with a comparison group because 
of the lack of formal evaluations/studies.
Data were extracted into a spreadsheet recording 
study bibliographic details, HR intervention details and 
key findings relating to the research aim.
As part of the rapid review approach, evidence was 
not subject to a robust quality appraisal but details of 
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the type of evidence, study design and expert affiliation 
were extracted to allow a limited assessment of quality.
A narrative synthesis approach was used to collate and 




In total, 121 pieces of evidence were identified, these 
included 106 from the systematic searches plus a further 
15 from citation searching and the targeted search for HR 
messaging. After de-duplication, 86 pieces of evidence 
were entered into the second round of screening.
Twenty-six pieces of evidence were excluded after 
abstract screening (see Table  2), leaving 60 pieces of 
evidence identified as appropriate for inclusion in the 
review. The majority (n = 20) of these exclusions were 
due to no information about HR interventions. Appen-
dix 2 outlines the key details of the included studies (see 
Additional file 2).
Of the 60 pieces of evidence identified, 48% (n = 29) 
were expert opinion pieces (of which most were aca-
demic experts).
There were also 11 studies (mainly case reports, 
descriptive or qualitative). In instances where multi-
ple reports were available from the same study, this was 
included as one piece of evidence.
There were four non-peer reviewed evidence reviews 
included.
The review covered 16 pieces of grey literature classi-
fied as guidance, which included COVID-19-related HR 
messaging for PWID. This type of messaging was not 
always directly available on Government websites but 
they often sign-posted to messaging produced by repu-
table non-Governmental organizations (NGOs), think-
tanks or service providers so these have been included.
Based on the types of evidence included in the review, 
the quality would be considered low-moderate.
Table 3 shows the range of countries that the pieces of 
evidence were from.
Narrative synthesis
Designating HR services as essential
Designating HR services as essential, so that they are not 
suspended in the event of a pandemic-type scenario, has 
been recommended by many experts [7, 8] and globally 
recognized bodies, including the International Society of 
Addiction Medicine (ISAM) [9], the International Net-
work of People who Use Drugs (INPUD) [10] and the 
European Monitoring Centre for Drugs and Drug Addic-
tion (EMCDDA) [2]. Continued unrestricted access 
to HR services, such as NSP [9], could be facilitated by 
ensuring an adequate supply of personal protective 
equipment (PPE) for staff [7, 11, 12]. There is no clear 
consensus, however, on which HR interventions to prior-
itize when staff or resources are limited.
By designating HR as essential, these services can 
not only sustain their vital work but also offer addi-
tional functions [13]. For instance, as PWID are likely 
to be more vulnerable to any pandemic disease, and the 
impacts of their substance misuse may mask or mimic 
disease symptoms, frequent screening for the pandemic 
infection within HR services is recommended [9, 14]. 
Additionally, supplies of sanitizing materials can be 
included within HR packs [14, 15].
An initiative to provide ‘essential journey’ cards, that 
PWID may use when collecting medications during 
lockdown to demonstrate their journey is essential, is 
yet to be evaluated but has been recommended by some 
authors [16, 17].
Continued access to blood-borne virus (BBV) testing 
and treatment for PWID is vital to identify cases and 
reduce transmission [13]; innovative ways to deliver this, 
such as rapid testing, need to be identified [14].
Developing emergency plans
Emergency preparedness of HR services needs improv-
ing [22]. This may include developing contingency plans, 
such as for periods of equipment or medication short-
age, which detail how HR services will be maintained 
(e.g., outreach, home delivery, virtual/phone consulta-
tions) [2, 11, 15]. The Larney and Bruneau (2020) review 
of the impact of ‘big events’ on substance misuse services 
emphasized the importance of emergency planning and 
reported that they found no publications describing how 
Table 2 Inclusion criteria used for second screen
Factor Criteria
Population PWID
Intervention Any HR intervention
Situation Similar to COVID-19 pandemic
Table 3 Included evidence by country
Country Evidence 
(n = 60)
Canada and USA 25
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HR and drug treatment service providers should prepare 
for an emergency [19].
Adjusting HR services to comply with social distancing
Numerous papers have recommended ways in which HR 
services can remain open and comply with social distanc-
ing [20] such as through adjusting patient flow [11] or 
mechanical segregation [21]; the methods suggested for 
specific HR interventions are detailed below.
NSP
In terms of NSP, various alternatives to conventional col-
lection are possible. For instance, a UK study concluded 
that home delivery, provision by post, peer-supported 
distribution and vending machines should be considered 
[22]. The authors of the UK study acknowledge that vend-
ing machines may be challenging to get in place quickly 
because of their sourcing and installation. They also point 
out that there are already direct postal sales of injecting 
equipment to some people who inject image and per-
formance enhancing drugs so establishing free postal 
needle/syringe provision to all PWID could be relatively 
easily achieved by utilizing existing delivery services [22]. 
However, evidence of how such services should be coor-
dinated and associated governance considerations has 
not yet been established.
Other authors also recommend vending machines, 
which provide 24-h access, and no-contact collection [7, 
8]. The LUCID-B study in Bristol reported positive feed-
back from PWID in relation to home delivery because it 
meant they did not have to travel, it kept them safe from 
COVID-19 and it prevented re-use of equipment [23].
The Larney and Bruneau (2020) review of evidence 
from other ‘big events’ concluded that, in a pandemic-
type scenario, NSP should offer as many needles and 
syringes to clients as requested and that flexible NSP, 
such as mobile or outreach models, will increase 
access [19]. Other authors have also recommended this 
‘low threshold’ approach (as opposed to one-for-one 
exchange) to needle/syringe provision [7, 24].
OST
Similar to NSP, outreach and home delivery have been 
recommended for OST in a pandemic-type situation 
[15, 25]. Flexibility for services to relax supervision and 
increase take home doses has also been suggested [8, 
12, 13, 15, 21]. Many authors state that these changes 
should be based on the stability of the patient, with high-
est risk patients still able to access the clinic [9, 16, 26–
28]. Clearly there are inherent risks in this approach but 
methods, such as the use of technology (e.g., “smart” pill 
bottles/lock boxes that dispense doses on a remotely set 
timescale), would mitigate them [29].
This review found examples of new models of deliv-
ery of OST services. For instance, in Rhode Island USA, 
regulatory changes meant that initiation of OST by tele-
phone could be developed; whilst the authors are positive 
about this approach, it has not yet been evaluated [30].
In Ireland, a model of remote care has been developed 
which begins with an assessment of COVID-19 risk by 
telephone followed by a single-patient visit to local ser-
vices to provide a point of care drug screen and complete 
necessary documentation. Contact episodes are main-
tained through remote video assessment and ongoing 
management by a primary care addiction specialist. This 
model is yet to be evaluated but it appears to offer lower 
COVID-19 transmission risks, increased access to OST 
and reduced waiting times [31].
Much of the evidence makes recommendations around 
telehealth [14, 25, 32, 33] as well as describing other tech-
nology that HR services could utilize, including smart-
phone and web-based interventions, text messaging 
for continuing contact and care, machine learning and 
wearable devices, including digital phenotyping and eco-
logical momentary assessment, biofeedback and virtual 
reality [34, 35]. Lead time and availability of technology 
(for both services and clients) will limit implementation 
of these options in the short term with text-messaging, 
smartphone and web-based interventions being the most 
simple and quick to roll-out.
One USA telehealth provider, Bicycle Health, has 
reported how it adapted its services to respond to 
COVID-19 guidance, such as urine testing via video link 
[36]. However, others have highlighted potential prob-
lems with these virtual solutions, such as the patient not 
having access to a private space for the call [29], and the 
risk of exacerbating inequalities which is considered fur-
ther below.
Several authors suggested buprenorphine as a safer 
take home option than methadone [29, 31, 37] and pro-
viding it as depot (long-acting injection) was recom-
mended [8, 38].
Naloxone
There is conflict between social distancing and the physi-
cally, socially and emotionally intimate nature of injecting 
drug use [39]; for instance, naloxone, as a HR interven-
tion, relies on social connections. Several authors have 
suggested, that during a pandemic-type situation, nalox-
one should be made more accessible (with appropriate 
patient and family education) because of the increased 
overdose risk resulting from using drugs alone when 
socially distancing and due to uncertain supply [29, 35].
One author suggests virtual injection supervision, 
which allows individuals to inject in the presence of an 
observer on the internet who is prepared to intervene in 
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the event of an overdose or virtual peer support which 
also uses the internet to make social support available 
to PWID at a physical distance [39]. Alternatively a USA 
study of NSP changes during COVID-19 recommended 
scheduling a phone check-in after use for people who are 
using alone [14].
Safe supply
Several authors have suggested ‘safe supply’ (defined as 
a legal and regulated supply of drugs that traditionally 
have been accessible only through the illicit drug mar-
ket) could provide a solution to the conflict between 
social distancing and HR [40, 41]. One piece of evi-
dence describes an unpublished study which found those 
receiving prescription alternatives to illicit drugs are able 
to avoid more routine contacts with drug dealers and can 
reduce activities that might put them at risk of acquir-
ing or transmitting pandemic infections (e.g., sex work); 
however, the authors acknowledge that a full evaluation 
is needed [42].
Role of Pharmacies
Many authors highlighted the important role of pharma-
cies in delivering HR interventions during a pandemic-
type situation if other services become unavailable [2, 
43–45]. However, at such times, pharmacies may have 
reduced opening hours [31]. PWID who participated in 
the LUCID-B study reported finding the long queues for 
pharmacies at the start of lockdown very off-putting [23].
Holistic approach
Much of the evidence suggested that HR needs to be part 
of a holistic approach to supporting PWID during a pan-
demic-type situation. For instance, several authors have 
emphasized the need for enhanced mental health sup-
port for PWID, with video or internet-based psychother-
apy and phone counseling generally recommended [9, 11, 
18, 19, 38].
Messages about how to access healthcare have been 
recommended as PWID may no longer have opportun-
istic access to treatment service staff and, therefore, may 
miss discussing wider physical health issues [23].
Links to social and economic services were also 
emphasized as important. For instance, ‘Housing First’ 
was highlighted as an approach which can facilitate social 
distancing and provide stability for PWID to engage in 
HR and manage extended OST take home doses appro-
priately [33, 34]. With increased duration of take home 
OST, one review concluded that accommodation for the 
homeless should have capacity for the safe storage of 
medications and space to designate as a safer use room 
[38].
Inequalities
A pandemic-type scenario has the potential to exacerbate 
health inequalities already experienced by PWID, such as 
increased morbidity and mortality and reduced service 
provision [33]. Additionally, much of the evidence indi-
cates a risk of widening inequalities within the injecting 
drug population by moving to interventions that require 
PWID to have access to a particular level of technology 
to be able to engage [29, 32, 34, 35, 39]. Providing mobile 
phones to clients [23, 29] or using peers to engage with 
the most marginalized PWID in their community [22, 24] 
are suggested strategies to mitigate this risk.
Overall, in the available evidence, there was little con-
sideration of sub-groups within the population who 
inject drugs; one Ukrainian study considered older peo-
ple as a sub-group of PWID finding that they need social 
support to engage in care [46] while another piece of evi-
dence suggested needles/syringes should be provided by 
home delivery for PWID living in non-urban areas [7].
The Larney and Bruneau (2020) review found few 
studies considered the impact of ‘big events’ specifi-
cally on women meaning there is limited evidence to 
inform women-specific and gender-sensitive COVID-19 
responses for women who use drugs. They suggest this is 
important because women who use drugs are vulnerable 
to gender-based violence, and scarcity of drugs is likely to 
exacerbate conflict and risks of exploitation and/or vic-
timization [19].
HR messaging
Developing a communications plan, at individual service 
level, is suggested in the literature [15]. Other authors 
stress that HR information materials should be made 
inclusive by ensuring they are suitable for various cul-
tures, available in different languages/formats [16] and 
distributed through multiple new channels of commu-
nication, such as mobile apps, peer networks and social 
media sites [16, 23, 26].
Due to the lack of evidence on HR messaging, a search 
was done of the communications provided during the 
COVID-19 pandemic by key national bodies and service 
providers. With the exception of the USA [47], Govern-
ment websites did not tend to provide direct messaging 
for PWID but they did sign-post to other independent 
resources which have been included in this review.
Important HR messages identified in this review can 
be grouped under the themes of infection control, and 
uncertain drug supply as detailed below: -
Messaging relating to infection control
Most of the messaging considered in this review included 
COVID-19-related hygiene advice, such as hand washing 
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and cleaning surfaces [47–54]. This was also highlighted 
by a group of Canadian experts [15] and many other 
authors stated the importance of using HR services to 
educate about infection control measures [2, 8, 14, 24, 33, 
38].
Cleaning the packages that drugs are supplied in (e.g., 
with alcohol wipes) was covered in some messaging [49, 
51, 52] and expert opinion [15]. Not carrying drugs pack-
ages in the body (e.g., mouth, rectum, vagina) was also 
mentioned [49, 52, 54].
Advice for PWID to prepare drugs themselves and 
avoid sharing equipment was common to almost all the 
messaging included in this review and was backed up 
with guidance around stocking up on supplies of equip-
ment (such as needles and syringes) [47–49, 49–56]. 
Most authors suggested at least two weeks [48, 51, 52, 54] 
supply of equipment but some recommended 3–4 weeks’ 
worth [49, 53]. Some messaging went on to include 
advice on how to clean syringes in the event of running 
out of supplies [4, 47, 51, 53].
A Canadian expert group also suggest that public 
health messages around self-isolation and social dis-
tancing should be modified for people who use drugs, 
who live in shelters or who are involved in sex work [15]. 
Some of the messaging included in the review did specifi-
cally provide advice for sex workers to limit close contact 
[48, 53].
The USA Government guidance explicitly recommends 
that PWID make use of the other services offered by NSP 
such as testing for BBV [47] while the WHO suggests HR 
messaging should be used to dispel myths that substance 
use somehow protects a person from infection [12].
Messaging relating to uncertain drug supply
An international group of experts recommended that 
messaging needs to include information about overdose 
risks associated with changes in the quantity and qual-
ity of the drugs market [24] and most of the messag-
ing included in this review did cover this. For instance, 
advice for PWID included using a test dose, or small 
amount, initially to see how it makes them feel [47, 48, 
51, 55]. Some messaging advised stocking up on drugs/
having a reserve in case of shortages [49, 53, 54] with oth-
ers warning about the legality and dangers of obtaining 
large amounts of drugs [48, 52]. One USA study also con-
cluded that educating participants on the increased risks 
of overdose through supply disruptions should include 
advice to cautiously increase personal supply in the event 
of a shortage [14].
Most messaging followed on from explaining the sup-
ply issue with advice about reducing the risk of overdose 
by accessing naloxone or by making a plan with family or 
friends to check in after using drugs [47–51, 53–56].
Guidance on managing involuntary withdrawal, such 
as stocking up on medications to relieve symptoms, was 
mentioned in much of the messaging because of the risk 
of drugs being in short supply or PWID not being able to 
access them due to self-isolation [48–54].
One of the UK service providers advises PWID to 
consider snorting rather than injecting during the pan-
demic as it is less risky when the quality of supply is 
unknown. They also suggest administering doses slowly 
when injecting to allow the drug to take effect, in order to 
reduce the likelihood of accidental overdose [55].
Discussion
This rapid review found 60 pieces of evidence relating to 
HR interventions and messaging in a pandemic-type situ-
ation and, through narrative synthesis, has identified the 
following implications for HR services, HR communica-
tion and further research.
Implications for HR services
HR services should prepare for future pandemics by 
developing emergency plans and involving relevant 
PWID advocacy groups in redesigning services. This 
review focused on interventions so found little evi-
dence on the role of operational partnerships, and work-
ing with organizations who support PWID, but these 
would be important for the implementation of, and may 
have implications on effectiveness of, interventions and 
messaging.
Government and commissioning organizations should 
ensure that HR services are designated as essential and 
take action to facilitate maintained provision (e.g., by 
providing appropriate PPE). There is no consensus from 
the evidence on which HR interventions to prioritize so 
local areas should base this on the needs of their popu-
lation. As essential services, HR providers could take 
on additional functions such as screening clients for the 
pandemic infection and testing for BBV.
To ensure equitable access, all NSP should be modi-
fied to enable social distancing (e.g., delivery rather than 
collection) and should have a low threshold for supply of 
injecting equipment.
A key message from the evidence is that complying 
with social distancing requires a more flexible approach 
to OST. This could be in terms of relaxing supervision 
and increasing take-home doses as well as considering 
more innovative ways of delivering OST services (such as 
telehealth and other technology). However, action must 
be taken to mitigate possible widening of inequalities; 
this might include provision of mobile phones to clients 
or targeted use of peer supporters.
Due to an increased risk of overdose [43], access to 
naloxone is particularly important during a situation such 
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as a global pandemic; therefore, services should employ 
innovative strategies to overcome the conflict with social 
distancing (such as through virtual support) and work 
with clients to identify suitable contacts (i.e., from their 
household or ‘bubble’).
Strong partnerships between HR services and other 
services (particularly pharmacies, housing providers and 
physical and mental health care services) are needed in 
order to offer a holistic approach. For instance, HR ser-
vices should work with homeless accommodation provid-
ers to ensure they can provide safe storage of medications 
and space for a safer use room.
Evidence from an international group of experts con-
cludes that consultation with PWID advocacy groups is 
needed when designing HR services that can respond to 
pandemic-type situations [58].
Looking to the future, several authors suggest that the 
COVID-19 pandemic response has provided an opportu-
nity for much needed change in the delivery of HR ser-
vices [34, 35, 44]. Innovations and regulatory changes, 
such as flexible OST dosing and dispensing, made dur-
ing the COVID-19 pandemic need to be evaluated and, if 
effective in a non-pandemic situation, sustained into the 
future [10, 31, 44, 45, 59].
Implications for HR communications
This rapid review found limited evidence on HR messag-
ing during a pandemic-type situation but by including a 
targeted search of HR messaging from key national and 
service provider websites the following implications have 
been identified.
HR services should develop a communications plan, 
which uses multiple channels, to employ in the ongoing 
COVID-19 response or future pandemic-type situations. 
However, relaying HR messages to PWID during a pan-
demic is so vitally important that government websites 
should include messaging directly for PWID and not rely 
on signposting to service providers or NGOs.
HR messaging should include advice on issues of infec-
tion control and uncertain drug supply, as well as key 
information about accessing HR and other services to fit 
with a holistic approach; these messages are summarized 
in Fig. 1.
Further research
To meet an urgent need for evidence and guidance, this 
rapid review did not include a systematic quality assess-
ment of the evidence but a brief appraisal revealed 
most was non-peer reviewed, pre-publication or expert 
opinion and so would be considered of low-medium 
quality. Thus, further research to evaluate the innova-
tions and changes to HR services and messaging dur-
ing the COVID-19 pandemic is urgently needed. This is 
particularly important as many experts feel that these 
changes should be sustained into the post-pandemic era 
so the impacts, both intended and unintended, require 
robust assessment. Additionally, the majority of evi-
dence is opiate focussed, which likely reflects the main 
cohort accessing services, but suggests a need for further 
focussed work with non-opiate clients.
This conclusion agrees with that of a rapid review con-
ducted by the National Collaborating Centre for Methods 
and Tools in Canada, in that little evidence is available 
on the effectiveness of strategies to mitigate the harmful 
effects of illicit drug use during the COVID-19 pandemic 
[60]. Specifically, evidence around HR messaging during 
a pandemic-type situation is particularly lacking.
Limitations
As previously stated, this rapid review presents pre-
liminary findings of an emerging evidence base. It 
only includes evidence available until 14/08/2020. The 
COVID-19 pandemic is still ongoing and new evidence 
is becoming available all the time. Further robust system-
atic reviews are needed to confirm the findings as the evi-
dence base expands.
Searches were restricted to English language evidence 
only which is likely to have excluded useful evidence 
from areas such as Eastern Europe. In fact, much of the 
evidence was from the USA and Canada so is likely to be 
most applicable to higher-income countries.
Time and resource constraints also meant that most of 
the searches, screening and data extraction was done by 
just one member of the review team. While this ensured 
consistency, it does risk bias in what evidence was 
included and excluded.
In response to a lack of evidence on HR messaging, a 
targeted approach was taken to find additional messaging 
aimed directly at PWID from key national and services 
provider websites based on author knowledge of relevant 
national stakeholders. A further detailed, systematic 
search of the grey literature may glean more results, as 
would exploration of emerging channels of communica-
tion (such as apps) which were not explicitly investigated 
in this review.
Conclusions
Preliminary findings from this rapid review suggest that 
HR services should be considered as essential during 
a pandemic and should be encouraged to operate flex-
ibly to best meet the needs of their local community of 
PWID. Additionally, working with partners to offer holis-
tic client-centered support is crucial.
The evidence on HR communication during a pan-
demic is scarce but the targeted search has identified 
key messages around infection control, uncertain drug 
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Fig. 1 Summary of HR messaging during a pandemic situation
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supply and accessing services which should be delivered 
via multiple channels.
Of overarching importance is awareness of, and action 
to mitigate, exacerbation of inequalities through over-
reliance on new remote and technology-based service 
delivery which may exclude the most marginalized.
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